All Oncology News

Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.

Neeraj Agarwal, MD, discusses a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors in the treatment of patients with renal cell carcinoma.

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.

Elizabeth Plimack, MD, discusses updated data from the pivotal CheckMate-025 trial, which compared the use of nivolumab with everolimus in the treatment of patients with metastatic renal cell carcinoma.

Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.

Carolyn E. Banister, MD, discusses the results of a study that uncovered a new subtype of cervical cancer, as well as some of the remaining challenges in the overall treatment landscape.

Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.

David Albala, MD, discusses the uses and benefits of robotic urological surgery in prostate cancer, as well as methods to achieve better physician compliance.

Franco M. Muggia, MD, discusses the results of the Gynecologic Oncology Group (GOG) 252 trial and what the findings mean regarding intraperitoneal therapy for patients with ovarian cancer.

Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

David F. McDermott, MD, discusses ongoing efforts to improve outcomes in advanced renal cell carcinoma through combination anti–VEGF/PD-1 regimens.

The tyrosine kinase inhibitor axitinib has been standard in the management of advanced renal cell carcinoma for about 5 years now, but the emergence of new agents has made some members of the oncology community concerned that its significance will be overlooked in favor of more recently approved treatments.

Scientists from the Sidney Kimmel Cancer Center at Thomas Jefferson University have pinpointed a survival protein for patients suffering from non-Hodgkin's lymphoma.

Researchers at Yale Cancer Center and Yale Medicine have identified the critical target of new immune-checkpoint therapies: subsets of immune cells called tissue resident memory (TRM) T cells. In the same research, scientists also found that individual metastatic cancer lesions contain unique sets of TRM cells.

To better understand how cancer initiates and spreads, Yale associate professor of pathology Qin Yan turned to the field of epigenetics, which examines changes in the expression of genes and proteins that do not affect the underlying genetic codes.

The regular use of aspirin lowers the risk for pancreatic cancer by almost 50 percent, a new study in China led by the Yale School of Public Health finds.

A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers.

Half of the patients in a Wisconsin Oncology Network (WON) clinical trial for a rare blood cancer are still in remission eight years after beginning treatment, according to new results of a follow-up to the study.

Regional Cancer Care Associates has continued its expansion along the East Coast by adding 2 Connecticut-based cancer centers with 6 cancer specialists to its network of independent practices.

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.

A sharp decline has been observed in the overall rate of men receiving treatment for prostate cancer.

A direct assessment of the uterine microbiome in patients with endometrial cancer has revealed a potential predictive role for vaginal microbes.

Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.

Since the FDA approval of nivolumab in May 2016, researchers continue to explore agent as well as its fellow PD-1 inhibitor, pembrolizumab, in various treatment settings for patients with Hodgkin lymphoma.

Data from the phase II PERTAIN trial presented late last year at the 2016 San Antonio Breast Cancer Symposium showed that adding an aromatase inhibitor (AI) to pertuzumab and trastuzumab extended progression-free survival by over 3 months versus trastuzumab plus an AI in patients with HER2-positive, HR-positive locally advanced or metastatic breast cancer.

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.

Guru Sonpavde, MD, discusses challenges with sequencing in advanced renal cell carcinoma and his vision for the field going forward.

Denise A. Yardley, MD, discusses the phase II tnAcity trial, the current role of nab-paclitaxel in triple-negative breast cancer, and the potential for using nab-paclitaxel in combination with immunotherapy in this setting.

Activating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.

Cota, a New York-based precision informatics company, has developed what it says will be a significant aid for oncology practices working to conform to the expectations of CMS’s Oncology Care Model, which is designed to encourage physicians to strive for better patient outcomes and lower costs.